Received: 9 October 2020
Accepted: 16 October 2020
First Online: 11 November 2020
: S.J.B. receives support from the National Institutes of Health, FDA, PCORI, the Rheumatology Research Foundation’s Scientist Development Award, the Childhood Arthritis and Rheumatology Research Alliance, and consulting for UCB. L.S.’s authorship of this manuscript was supported by the U.S. Food and Drug Administration under the Global Pediatric Clinical Trials Network, Award Number 5U18FD006298. R.R. receives support from the National Institute of General Medical Sciences and the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number T32GM086330. R.R.’s spouse has current or prior employment and/or stock ownership in Merck & Co. and Biogen. R.J.C. has no disclosures to report. M.E.L. receives salary support from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number (K23NS116453). C.P.H. receives salary support for research from National Institute for Child Health and Human Development (NICHD) (R13HD102136), the National Heart Lung and Blood Institute (NHLBI) (R61/R33HL147833), the US Food and Drug Administration (R01-FD006099, PI Laughon; and U18-FD006298, PI Benjamin), the U.S. government for his work in pediatric clinical pharmacology (Government Contract HHSN275201800003I, PI: Benjamin under the Best Pharmaceuticals for Children Act), the non-profit Burroughs Wellcome Fund, and other sponsors for drug development in adults and children (ExternalRef removed).
Free to read: This content has been made available to all.